AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03833570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconaz oral gel
Description: Antifungal agent
Study NCT02211196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01455298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transient Elastography and fibrotest
Description: a Transient Elastography and an ultrasound are performed.
Study NCT01782430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: - standard oxygenation
Study NCT01782430 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: - standard oxygenation
Study NCT04716868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Fructans 5 g
Description: Agave tequilana Weber blue variety 5 g once a day for 8 weeks
Study NCT04716868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Fructans 10 g
Description: Agave tequilana Weber blue variety 10 g once a day for 8 weeks
Study NCT04716868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Fructans 5 g + Maltodextrin 10 g
Description: Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks
Study NCT04716868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium plantago
Description: Psyllium plantago 15 g once a day for 8 weeks
Study NCT03020589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: See description in arm/group sections
Study NCT04226950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Interferon Alpha
Description: Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers;
Study NCT04226950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Description: Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
Study NCT03833570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent
Study NCT03833570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent
Study NCT03833570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oracure gel
Description: Topical analgesic gel
Study NCT03833570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracure gel
Description: Topical analgesic gel
Study NCT03833570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkamisr sachets
Description: Sodium bicarbonate mouthwash
Study NCT03833570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkamisr sachets
Description: Sodium bicarbonate mouthwash
Study NCT02960646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02960646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT02960646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02960646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02960646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02960646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo CD45RA depleted peripheral blood stem cell transplantation
Study NCT02960646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02960646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT02960646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT02625363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread with 125 ml water (twice)
Description: Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study NCT04290741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular (Battlefield) Acupuncture
Description: Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
Study NCT04290741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Acupuncture
Description: Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
Study NCT04346875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regularly changing of dressing
Description: Conventional dressing
Study NCT04346875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No application
Description: No dressing change
Study NCT01242072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifosfamide-tris
Description: Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
Study NCT01842191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
Study NCT01842191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
Study NCT04373447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lap fundus-calot cholecystectomy
Description: use laparoscopic fundus-calot approach
Study NCT04373447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open cholecystectomy
Description: use open approach
Study NCT00353873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: 200μg twice daily
Study NCT04493359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors
Description: switch anti-hypertensive class
Study NCT00912171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide (Aircort 50 nasal spray)
Description: 50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
Study NCT00912171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast (Singulair)
Description: Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
Study NCT04377542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: Ligation of the fistula tract in the intersphincteric plane
Study NCT04377542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parks
Description: Modified Parks fistulotomy with complete internal anal sphincterotomy
Study NCT04377542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seton
Description: Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
Study NCT01436214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC-100
Description: Daily oral, dose escalation, 28-day cycle(s)
Study NCT02589457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-390
Description: Tenofovir Disoproxil Aspartate 1T PO
Study NCT02589457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread® tablet
Description: Tenofovir Disoproxil Fumarate 1T PO
Study NCT00824408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 i.v. on day 1 of 21 day cycle
Study NCT00824408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/m\^2 i.v. on day 1 of 21 day cycle
Study NCT00824408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727 i.v. on day 1 of a 21 day cycle
Study NCT03631966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport
Description: BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
Study NCT00353873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Description: 50/100μg twice daily
Study NCT06510088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-week multimodal prehabilitation program
Description: This program included four components:~Aerobic and Resistance Exercises A designated physical therapist supervises the resistance exercises and offers corrective guidance. Training intensity was continuously monitored and fine-tuned based on Borg scale assessments.~Respiratory Training Respiratory training was conducted using a respiratory trainer. Patients were instructed to engage in respiratory training at least three times daily, with each session lasting 10 minutes.~Nutrition Intervention Those in the multimodal prehabilitation group received daily whey protein powder to ensure a recommended protein intake of 1.5 g/kg/d. Protein supplements were to be consumed within one hour of exercise to promote muscle synthesis.~Psychological Intervention Anxiety-coping interventions included relaxation techniques and deep breathing exercises, administered in a one-to-one format by a nurse trained in psychological care.
Study NCT05566457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs
Description: Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
Study NCT01888484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octanorm 16.5%
Description: octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
Study NCT02971215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux Laser
Description: Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~+ Physical Therapy protocol.
Study NCT02971215 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ilux Laser
Description: Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
Study NCT00553332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given orally
Study NCT00553332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02124356 — intervention group
Intervention type: OTHER
Intervention: Evaluation of functional performance
Study NCT03650543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin clarithromycin omeprazole 1
Description: Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
Study NCT03650543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin clarithromycin omeprazole 2
Description: The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
Study NCT02508441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andes-1537 for Injection
Description: Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle
Study NCT01536366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 25 mg BIA 9-1067 (single-dose)
Study NCT01536366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: 0.5 mg repaglinide (single-dose)
Study NCT01590134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement of iron
Description: 1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
Study NCT01590134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: 200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
Study NCT05026970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Electrostimulation+Kegel
Description: Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
Study NCT05026970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Tibial Neuromodulation+Kegel
Description: Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
Study NCT05026970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Kegel
Description: Biofeedback+Kegel exercises
Study NCT02744066 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NEATCAP
Description: Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
Study NCT04554394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX Device
Description: The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
Study NCT02984735 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
Study NCT02258841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Setting Priorities for Safety
Description: Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
Study NCT02258841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Danger Assessment
Description: Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
Study NCT02258841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Action Plan
Description: Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
Study NCT02258841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General risk and safety information
Description: Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
Study NCT02258841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Emergency Safety Plan
Description: Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
Study NCT00859144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Be Proud! Be Responsible!
Description: This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
Study NCT00859144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Becoming A Responsible Teen (BART)
Description: This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
Study NCT00859144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Description: This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
Study NCT00082628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to serostim® as subcutaneous injection.
Study NCT00082628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to serostim® as subcutaneous injection.
Study NCT00082628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim® 4 mg
Description: Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
Study NCT00082628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim® 2 mg
Description: Serostim® 2 mg as subcutaneous injection on alternate days.
Study NCT01766401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01766401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazadone
Description: Viibryd
Study NCT02342652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
Study NCT02342652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
Study NCT01990625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antenatal Ultrasound Scan
Description: Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
Study NCT01020994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41003
Description: Once daily, topically
Study NCT01020994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189962
Description: Once daily, topically